A federal court finds that W.L. Gore was not a co-inventor of vascular grafts patented by C.R. Bard, affirming a lower court's $371 million decision in favor of Bard. Analysts weigh in and Wall Street gives Bard some love.
Updated Feb. 10, 2012, at 1:30 p.m. with share values and analysts' reactions.
A U.S. federal judge this week upheld C.R. Bard's (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
The court affirmed Bard's $371 million win from a 2007 decision when an Arizona jury found that Gore willfully infringed on patents for vascular tubing.
"This has been a long and arduous journey for the parties in this litigation, but this should be the final curtain of the saga," Circuit Court Judge Arthur Gajarsa of the U.S. Court of Appeals for the Federal Circuit wrote in the decision.
The news gave Bard a bump on The Street where shares were trading 2% higher at $94.36 around 1:30 p.m. today.
"Though not unexpected, this is a positive milestone for BCR," Leerink Swann analyst Rick Wise wrote in a letter to shareholders. "Our understanding is that although Gore still has several possible levels of appeals, from a practical manner, the court's ruling today will likely be very much what the final ruling will look like."
Wise predicted an earnings upside of around $1.40 to $1.50 per share as a result of the ruling. With total damages and an ongoing royalty stream considered together, Bard stands to rake in about $783 million.
The decision was split 2 to 1 and Judge Gajarsa was rather candidly dismissive of the dissenting opinion:
Intersect ENT enrolls the 1st patient in its PROGRESS study, aiming to expand the patient population...
Innovative needle design to enhance patient safety.
Medtronic taps Dr. Elizabeth Nabel, president of Brigham & Women's Faulkner Hospital in Boston,...
NxStage Medical wins FDA clearance to market its OneSite single needle dialysis technology for use...